722 related articles for article (PubMed ID: 32644148)
1. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial.
Jackson TL; Soare C; Petrarca C; Simpson A; Neffendorf JE; Petrarca R; Muldrew A; Peto T; Chakravarthy U; Membrey L; Haynes R; Costen M; Steel D; Desai R;
JAMA Ophthalmol; 2020 Aug; 138(8):835-842. PubMed ID: 32644148
[TBL] [Abstract][Full Text] [Related]
2. Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration (MERLOT): A Phase 3 Randomized Controlled Trial.
Jackson TL; Desai R; Simpson A; Neffendorf JE; Petrarca R; Smith K; Wittes J; Lewis C; Membrey L; Haynes R; Costen M; Steel DH; Muldrew A; Chakravarthy U;
Ophthalmology; 2016 Jun; 123(6):1287-96. PubMed ID: 27086023
[TBL] [Abstract][Full Text] [Related]
3. Macular epiretinal brachytherapy in treated age-related macular degeneration: MERITAGE study: twelve-month safety and efficacy results.
Dugel PU; Petrarca R; Bennett M; Barak A; Weinberger D; Nau J; Jackson TL
Ophthalmology; 2012 Jul; 119(7):1425-31. PubMed ID: 22465819
[TBL] [Abstract][Full Text] [Related]
4. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET).
Dugel PU; Bebchuk JD; Nau J; Reichel E; Singer M; Barak A; Binder S; Jackson TL;
Ophthalmology; 2013 Feb; 120(2):317-27. PubMed ID: 23174399
[TBL] [Abstract][Full Text] [Related]
5. Epimacular brachytherapy for previously treated neovascular age-related macular degeneration: month 36 results of the MERLOT randomised controlled trial.
Jackson TL; Soare C; Petrarca C; Simpson A; Neffendorf JE; Petrarca R; Muldrew KA; Peto T; Chakravarthy U; Membrey L; Haynes R; Costen M; Steel DHW; Desai R;
Br J Ophthalmol; 2023 Jul; 107(7):987-992. PubMed ID: 35217515
[TBL] [Abstract][Full Text] [Related]
6. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 24 safety and efficacy results.
Petrarca R; Dugel PU; Bennett M; Barak A; Weinberger D; Nau J; Jackson TL
Retina; 2014 May; 34(5):874-9. PubMed ID: 24169101
[TBL] [Abstract][Full Text] [Related]
7. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 12 optical coherence tomography and fluorescein angiography.
Petrarca R; Dugel PU; Nau J; Slakter JS; Jaffe GJ; Jackson TL
Ophthalmology; 2013 Feb; 120(2):328-33. PubMed ID: 23178157
[TBL] [Abstract][Full Text] [Related]
8. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography.
Jackson TL; Dugel PU; Bebchuk JD; Smith KR; Petrarca R; Slakter JS; Jaffe GJ; Nau JA;
Ophthalmology; 2013 Aug; 120(8):1597-603. PubMed ID: 23490325
[TBL] [Abstract][Full Text] [Related]
9. Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study.
Kertes PJ; Galic IJ; Greve M; Williams RG; Rampakakis E; Scarino A; Sheidow T
Ophthalmology; 2019 Jun; 126(6):841-848. PubMed ID: 30677465
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration.
Holz FG; Oleksy P; Ricci F; Kaiser PK; Kiefer J; Schmitz-Valckenberg S;
Ophthalmology; 2022 Jan; 129(1):54-63. PubMed ID: 33957183
[TBL] [Abstract][Full Text] [Related]
11. One-year results from clinical practice of epimacular strontium-90 brachytherapy for the treatment of subfoveal choroidal neovascularization secondary to AMD.
Zur D; Loewenstein A; Barak A
Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):338-43. PubMed ID: 25856820
[TBL] [Abstract][Full Text] [Related]
12. Aflibercept for neovascular age-related macular degeneration.
Sarwar S; Clearfield E; Soliman MK; Sadiq MA; Baldwin AJ; Hanout M; Agarwal A; Sepah YJ; Do DV; Nguyen QD
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD011346. PubMed ID: 26857947
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
Sahni J; Dugel PU; Patel SS; Chittum ME; Berger B; Del Valle Rubido M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Weikert R; Fauser S
JAMA Ophthalmol; 2020 Sep; 138(9):955-963. PubMed ID: 32729888
[TBL] [Abstract][Full Text] [Related]
14. Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration - results from the randomized, phase IIIb OCTAVE study.
Staurenghi G; Garweg JG; Gerendas BS; Macfadden W; Gekkiev B; Margaron P; Dunger-Baldauf C; Kolar P
BMC Ophthalmol; 2020 Jan; 20(1):18. PubMed ID: 31918685
[TBL] [Abstract][Full Text] [Related]
15. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
[TBL] [Abstract][Full Text] [Related]
16. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL
Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617
[TBL] [Abstract][Full Text] [Related]
17. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
Brown DM; Chen E; Mariani A; Major JC;
Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
[TBL] [Abstract][Full Text] [Related]
18. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study.
Jackson TL; Chakravarthy U; Kaiser PK; Slakter JS; Jan E; Bandello F; O'Shaughnessy D; Gertner ME; Danielson L; Moshfeghi DM;
Ophthalmology; 2013 Sep; 120(9):1893-900. PubMed ID: 23490327
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Changes in Submacular Choroidal Thickness after Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 14-Mo Follow-Up.
Inan S; Baysal Z; Inan UU
Curr Eye Res; 2019 Aug; 44(8):908-915. PubMed ID: 30909756
[No Abstract] [Full Text] [Related]
[Next] [New Search]
